Free · 13,591 studies indexed

lighttherapyresearch.com is a free index of research on photobiomodulation and light therapy, gathered from the world’s journals and trial registries.

Sections
Pain & Musculoskeletal

Optogenetic and chemogenetic strategies for sustained inhibition of pain

We demonstrate that the viral expression of the hM4D receptor in small-diameter primary afferent nociceptor enables chemogenetic inhibition of mechanical and thermal nociception thresholds.

Excerpt from the paper’s abstract. Read the full paper for the details.

AI-generated summary

The authors studied mice, using genetic tools to make pain-sensing nerve fibers respond to light or a designer drug. They report that infrequent transdermal light pulses with the SwiChR channel persistently reduced pain, cutting required light exposure by more than 98 percent. They also report that the hM4D receptor allowed chemogenetic inhibition of mechanical and thermal pain thresholds, but these are animal findings.

Who or what was studied
unclear
Limits stated in the abstract
The abstract describes preclinical work and does not report human participants or a sample size.

Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.

Abstract

Spatially targeted, genetically-specific strategies for sustained inhibition of nociceptors may help transform pain science and clinical management. Previous optogenetic strategies to inhibit pain have required constant illumination, and chemogenetic approaches in the periphery have not been shown to inhibit pain. Here, we show that the step-function inhibitory channelrhodopsin, SwiChR, can be used to persistently inhibit pain for long periods of time through infrequent transdermally delivered light pulses, reducing required light exposure by >98% and resolving a long-standing limitation in optogenetic inhibition. We demonstrate that the viral expression of the hM4D receptor in small-diameter primary afferent nociceptor enables chemogenetic inhibition of mechanical and thermal nociception thresholds. Finally, we develop optoPAIN, an optogenetic platform to non-invasively assess changes in pain sensitivity, and use this technique to examine pharmacological and chemogenetic inhibition of pain.

Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.

How to read a single study: what to check before relying on this kind of research.

A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.

Related studies